ImmunityBio, Inc. / Fundamentals
Income statement
- Net revenue
€48.56M - Cost of goods sold
€166.45K - Gross profit
€44.85M - SG&A expenses
€130.38M - R&D expenses
€160.34M - EBITDA
-€156.59M - D&A
€10.70M - EBIT
-€244.85M - Interest expenses
€78.41M - EBT
-€314.79M - Tax expenses
€245.39K - Net income
-€314.97M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€32.00M - Changes in working capital
-€15.33M - Operating cash flow
-€299.92M - Capex
€6.10M - Other investing cash flow
-€640.93K - Net investing cash flow
€53.93M - Total cash dividends paid
€0.00 - Issuance of common stock
€225.76M - Debt repayment
-€22.31K - Other financing cash flow
€12.42M - Net financing cash flow
€253.39M - Foreign exchange effects
€68.64K - Net change in cash
€77.63M - Cash at end of period
€118.11M - Free cash flow
-€293.82M
Balance sheet
- Cash and cash equivalents
€118.11M - Cash and short-term investments
€131.84M - Total receivables
€19.16M - Inventory
€5.70M - Other current assets
€21.88M - Total current assets
€178.58M - Property, plant & equipment
€143.91M - Goodwill
€780.78K - Intangible assets
€12.07M - Long-term investments
€0.00 - Other non-current assets
€9.64M - Total non-current assets
€166.40M - Total assets
€344.98M - Accounts payable
€6.37M - Short-term debt
€6.34M - Other current liabilities
€30.74M - Total current liabilities
€43.45M - Long-term debt
€452.96M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€337.47M - Total non-current liabilities
€790.43M - Total liabilities
€833.89M - Common stock
€78.08K - Retained earnings
-€3.09B - Other equity
€10.78M - Total equity
-€488.91M - Total liabilities and shareholders' equity
€344.98M
Company information
- Market capitalization
€2.03B - Employees
671 - Enterprise Value
€2.84B
Company ratios
- Gross margin
-
92.3% Much better than peer group: -418,058.0% - EBITDA margin
-
-322.4% Much better than peer group: -352,346.1% - EBIT margin
-
-504.2% Much better than peer group: -348,579.7% - EBT margin
-
-648.2% Much better than peer group: -192,449.4% - Net margin
-
-648.6% Much better than peer group: -238,745.4% - ROE
-
64.4% Much better than peer group: -43.8% - ROA
-
-91.3% Much better than peer group: -265.4% - Asset turnover
-
14.1% Even with peer group: 17.4% - FCF margin
-
-630.1% Much better than peer group: -127,296.4% - FCF yield
-15.1% - Efficiency ratio
422.4% - Net sales per employee
-
€72.37K - Net income per employee
-
-€469.40K